Recent news on Esomeprazole Magnesium

New Studies Evaluating NEXIUM(R) In Pediatric GERD To Be Presented ...  -  May 22, 2007
PR Newswire (press release),NEXIUM (esomeprazole magnesium) received approval in April 2006 for the short-term treatment (up to 8 weeks) of GERD in adolescent patients aged 12 to 17.

Pozen Announces May 2, 2007 Webcast of First Quarter 2007 Results  -  Apr 18, 2007
PharmaLive.com (press release),...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for

Broadway Actress/HIV Advocate, Sheryl Lee Ralph, Unveils Winning ...  -  Apr 16, 2007
Drug Newswire (press release),...rifampin, St. John's wort (Hypericum perforatum), AcipHex(R) (rabeprazole sodium), Nexium(R) (esomeprazole magnesium), Prevacid(R) (lansoprazole),

Pozen Announces Trexima (Sumatriptan Succinate and Naproxen Sodium ...  -  Mar 23, 2007
PharmaLive.com (press release),...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for

FDA Approves To Review Amended Response Of Pozen's Trexima - Update  -  Mar 22, 2007
Trading Markets,The company has also entered alliance AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium

Pozen: On Track With New Pain Medications  -  Mar 12, 2007
Seeking Alpha,PN is a fixed-dose combination of the proton pump inhibitor [PPI] esomeprazole magnesium (Nexium) with the non-steroidal anti-inflammatory drug [NSAID]

Pharmas to lose $100bn to generics  -  Feb 23, 2007
DrugResearcher.com,...including blockbusters Norvasc (amlodipine) from Pfizer, AstraZeneca's Nexium (esomeprazole magnesium) and Janssen's Risperdal (risperidone),

POZEN To Present at the Susquehanna Financial Group Healthcare ...  -  Feb 19, 2007
dBusinessNews Triad (press release),...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for

POZEN to Present at the Wachovia Securities 2007 Small and Mid-Cap ...  -  18 Jan 2007
dBusinessNews Triangle (press release),...and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in a single tablet for

POZEN Names Gilda M. Thomas as Senior Vice President and General ...  -  Jan 10, 2007
dBusinessNews Charlotte (press release),...and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in a single tablet for

AZ' s value plunges by £2bn as it loses patent on top drug  -  Dec 19, 2006
Times Online,Ratiopharm first challenged the “novelty and inventiveness� of Nexium’s active ingredient, esomeprazole magnesium salt, in 2001. Its argument was rejected

New reports from AstraZeneca detailed.  -  Dec 14, 2006
Therapeutics Daily (subscription) (press release),...a new indication for the prescription proton pump inhibitor Nexium (esomeprazole magnesium) for the treatment of Zollinger-Ellison Syndrome (ZES).

POZEN To Present at the 2006 RBC Capital Markets Healthcare ...  -  Dec 8, 2006
dBusinessNews Triad (press release),...and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in a single tablet for

AZ' s value plunges by £2bn as it loses patent on top drug  -  Dec 19, 2006
Times Online,Ratiopharm first challenged the “novelty and inventiveness� of Nexium’s active ingredient, esomeprazole magnesium salt, in 2001. Its argument was rejected

US FDA approves Nexium for treatment of Zollinger-Ellison Syndrome  09 Nov 2006
...that the US Food and Drug Administration (FDA) has approved a new indication for the prescription proton pump inhibitor Nexium (esomeprazole magnesium) for the ... -Therapeutics Daily (subscription) (press release), POZEN Submits Full Response to FDA Approvable Letter For Trexima ...  09 Nov 2006
...the acute treatment of migraine, and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen ... -Genetic Engineering News (press release), FDA Approves New Formulation for Nexium (Esomeprazole Magnesium)  Oct 24, 2006
October 24, 2006 -- AstraZeneca today announced that a new formulation for its prescription proton pump inhibitor Nexium (R) (esomeprazole magnesium) has been ... -DG News FDA Approvals: Yaz, Betaseron, and Nexium  Nov 2, 2006
...beta-1b subcutaneous injection, allowing its use for the treatment of early multiple sclerosis; and a new indication for esomeprazole magnesium delayed-release ... -Medscape (subscription) FDA Approves New Formulation For NEXIUM  Oct 25, 2006
AstraZeneca (NYSE: AZN) today announced that a new formulation for its prescription proton pump inhibitor NEXIUM (R) (esomeprazole magnesium) has been approved ... -Medical News Today (press release), POZEN Reports Third Quarter 2006 Results  Oct 31, 2006
...agreement for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium, with the non ... -Business Wire (press release), FDA Approves NEXIUM for the Treatment of Zollinger-Ellison ...  Oct 12, 2006
...the US Food and Drug Administration (FDA) has approved a new indication for the prescription proton pump inhibitor NEXIUM(R) (esomeprazole magnesium) for the ... -PR Newswire (press release), New Nexium Formulation Approved  Oct 25, 2006
The FDA has approved a new formulation for AstraZeneca’s Nexium (esomeprazole magnesium). Nexium 20 and 40 mg delayed-release ... -Facts and Comparisons, Back To The Basics  Oct 27, 2006
...are trying to do is take the very safe NSAID, deproxin, and improve the gastrointestinal toxicity by combining it with the esomeprazole magnesium," said Pozen ... -Investor's Business Daily (subscription) FDA Approves NEXIUM for the Treatment of Zollinger-Ellison ...  Oct 17, 2006
AstraZeneca has announced that the FDA has approved a new indication for the prescription proton pump inhibitor NEXIUM® (esomeprazole magnesium) for the ... -Pharmaceutical Processing, FDA Approves NEXIUM for Treatment of Zollinger-Ellison Syndrome  Oct 19, 2006
...the US Food and Drug Administration (FDA) has approved a new indication for the prescription proton pump inhibitor NEXIUM® (esomeprazole magnesium) for the ... -EndoNurse, POZEN to Present at the Cowen & Company 7th Annual Global Health ...  Nov 1, 2006
Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in ... -Business Wire (press release), Codexis weighs into generics biz via India  Oct 12, 2006
...intermediates and APIs for infectious disease, cardiovascular and CNS indications, including AstraZeneca's Nexium (esomeprazole magnesium), with expansion ... -In-PharmaTechnologist.com, Nexium Approved for Additional Indication  Oct 16, 2006
AstraZeneca’s Nexium (esomeprazole magnesium) has been approved by the FDA for the treatment of Zollinger-Ellison Syndrome, a rare but serious chronic ... -Facts and Comparisons, AstraZeneca (AZN) Receives FDA Approval for NEXIUM for Treatment ...  Oct 12, 2006
...basal acid output control in this patient population. NEXIUM(R) (esomeprazole magnesium) was well tolerated throughout the trial. -StreetInsider.com (subscription), FDA Approves NEXIUM for the Treatment of Zollinger-Ellison ...  Oct 12, 2006
...control in this patient population. NEXIUM(R) (esomeprazole magnesium) was well tolerated throughout the trial. ZES affects fewer than ... -Earthtimes.org Pozen gets $40M milestone payment; raises revenue view  Sep 21, 2006
...agreement with AstraZeneca on August 1 to co-develop and commercialize fixed-dose combinations of the proton pump inhibitor esomeprazole magnesium, with the non ... -MarketWatch

POZEN Announces Receipt of $40 Million Upfront Payment from ...  Sep 21, 2006
1, 2006 for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium, with the ... -Business Wire

POZEN To Present at the 2006 RBC Capital Markets Healthcare ...  -  Dec 8, 2006
dBusinessNews Triad (press release),...and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in a single tablet for

POZEN and AstraZeneca Announce Global Collaboration to Co-Develop ...  Aug 2, 2006
...for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium, with the non ... -PipelineReview.com

Pozen To Collaborate With AstraZeneca To Co-Develop Fixed Dose ...  Aug 1, 2006
...for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor or PPI esomeprazole magnesium, with the non ... -Trading Markets

Pozen, AstraZeneca to Develop Pain Drug  Aug 2, 2006
...agreement calls for the companies to develop a pill that combines Pozen's nonsteroidal anti-inflammatory drug naproxen with esomeprazole magnesium, the active ... -Houston Chronicle

Friday's Health Winners & Losers  Aug 2, 2006
The drug, which contains the pain reliever naproxen and the stomach drug esomeprazole magnesium, is being tested to treat patients at risk for gastric ulcers ... -TheStreet.com

Shares of Pozen up nearly 30 percent after deal with AstraZeneca  Aug 2, 2006
The companies plan to develop a drug that combines Pozen's nonsteroidal anti-inflammatory drug naproxen with esomeprazole magnesium, the active ingredient in ... -Fayetteville Online

POZEN and AstraZeneca Collaberate On Research And Licensing Deal  Aug 2, 2006
...and commercialization of an arthritis pain reliever - a proprietary fixed dose combination of the proton pump inhibitor esomeprazole magnesium with the non ... -Carolina Newswire

NEXIUM(R) Maintains Healing Of Erosive Esophagitis Better Than ...  Jul 26, 2006
A new study involving more than 1,000 patients with healed erosive esophagitis (EE), reports that NEXIUM(R) (esomeprazole magnesium) is more effective than ... -Medical News Today

08/02 StreetInsider.com Unusual 11 Mid-Day Movers  Aug 2, 2006
NYSE: AZN) for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium, with the non ... -StreetInsider.com (subscription)



Heartburn drug prevents ulcers  Mar 27, 2006
...to be published in the April edition of The American Journal of Gastroenterology indicate that the acid-reflux drug Nexium (esomeprazole magnesium) can reduce ... - myDNA.com

Treatment Reduces Gastric Ulcers in at-risk Patients Using Long ...  Mar 31, 2006
...two clinical trials, to be published in the April 2006 edition of the American Journal of Gastroenterology, indicate that esomeprazole magnesium can reduce the ... - EndoNurse

Nexium Reduces Stomach Ulcers in High-Risk Patients  Mar 31, 2006
17 percent. The research was funded by the drug company AstraZeneca, which markets Nexium, known generically as esomeprazole magnesium. ... - Forbes

BARRX Medical, Inc. Initiates Landmark Study Comparing Two ...  Mar 20, 2006
AstraZeneca (NYSE: AZN), makers of NEXIUM(R) (esomeprazole magnesium), co-sponsors first study of radio frequency ablation therapy vs. ... - International News Service

New Study Compares Treatment Options For Pre-Cancerous Condition ...  Mar 26, 2006
...interval. All patients will receive esomeprazole magnesium (NEXIUM) as therapy for acid reflux disease as part of the study protocol. ... - Medical News Today

NEXIUM(R) Shown to Reduce Gastric Ulcers in At-Risk Patients Using ...  Mar 22, 2006
...trials, to be published in the April 2006 edition of the American Journal of Gastroenterology, indicate that NEXIUM(R) (esomeprazole magnesium) can reduce the ... - PR Newswire

AstraZeneca commences patent infringement litigation against IVAX  Mar 12, 2006
...and its US subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca's patents protecting NEXIUM® (esomeprazole magnesium). ... - Chemie.de

Santarus Announces Positive Results with ZEGERID in Nocturnal Acid ...  Mar 8, 2006
...study that evaluated ZEGERID(R) (omeprazole/sodium bicarbonate) Powder for Oral Suspension 40 mg/1680 mg, Nexium(R) (esomeprazole magnesium) delayed-release ... - Business Wire

Positive Results with ZEGERID in Nocturnal Acid Breakthrough ...  Mar 8, 2006
...study that evaluated ZEGERID® (omeprazole/sodium bicarbonate) Powder for Oral Suspension 40 mg/1680 mg, Nexium® (esomeprazole magnesium) delayed-release ... - EndoNurse

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional